Lymphocytes in Immunotherapy of Cancer /
This book summarizes various approaches in LAK therapy. The most important question is whether synergism or antagonism to other biological response modifiers plays a role in changing the immunological specificity of LAK cells. Combined administration of LAK cells and IL-2, intraarterial and intramur...
| Main Author: | |
|---|---|
| Corporate Author: | |
| Other Authors: | , , |
| Format: | eBook |
| Language: | English |
| Published: |
Berlin, Heidelberg :
Springer Berlin Heidelberg,
1989.
|
| Subjects: | |
| Online Access: | Connect to the full text of this electronic book |
Table of Contents:
- Therapy of Cancer with Interleukin-2-Activated Natural Killer Cells
- T Cell Heterogeneity and Function
- Human Lymphokine-Activated Killer Cells and Their Potential for Cancer Therapy
- In Vitro and in Vivo Induction of Lymphokine-Activated Killer Cells in Patients with Gastric Cancer and Other Solid Tumors
- Tests for Determination of Lymphocyte Activity
- Lysis of Autologous Tumor Cells by Blood Lymphocytes In Vitro Requires MHC Class I Antigen Expression
- Target Structures for Cellular Immune Mechanisms on the Surface of Epstein-Barr Virus-Infected Malignant and Nonmalignant Lymphocytes
- Human Lymphokine-Activated Killer Cells Activated with Interleukin-2 and Tumor Necrosis Factor- : Implications for Immunotherapy
- Interleukin-2 in the Treatment of Malignant Melanoma and Renal Cell Carcinoma
- Lymphokine-Activated Human Effector Cells Targeted by Monoclonal Antiganglioside Antibodies: A Preclinical Model for Immunotherapy of Human Melanoma
- Comments on the Problems of Immunotherapy with Autologous Lymphocytes
- A Clinician's Comments on Cancer Therapy with Lymphocytes.